Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (11-20 of 395) with videos related to

Pageof 40
Sort By:
Seminars in Oncology|March 20, 2003
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patientsRoy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Lung cancer in the era of precision medicineKaterina Politi, Roy S Herbst
Seminars in Oncology|December 10, 1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancerR S Herbst, R Lilenbaum
Seminars in Oncology|February 14, 2006
Use of novel second-line targeted therapies in non-small cell lung cancerErminia Massarelli, Roy S Herbst
Immunotherapy|February 11, 2016
Immune checkpoint therapy for non-small-cell lung cancer: an updateBing Xia, Roy S Herbst
Cancer Journal (Sudbury, Mass.)|August 8, 2014
B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future directionScott Gettinger, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Nivolumab and Pembrolizumab for Non-Small Cell Lung CancerDaniel Morgensztern, Roy S Herbst
Hematology/Oncology Clinics of North America|January 7, 2003
Angiogenesis as a target for cancer therapyKerim Kaban, Roy S Herbst
The Oncologist|November 11, 2008
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLCRoy S Herbst, Alan Sandler
The Journal of Clinical Investigation|June 5, 2008
To kill a tumor cell: the potential of proapoptotic receptor agonistsAvi Ashkenazi, Roy S Herbst
Pageof 40

Showing results (11-20 of 395) with videos related to

Sort By:
Pageof 40
Seminars in Oncology|March 20, 2003
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patientsRoy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Lung cancer in the era of precision medicineKaterina Politi, Roy S Herbst
Seminars in Oncology|December 10, 1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancerR S Herbst, R Lilenbaum
Seminars in Oncology|February 14, 2006
Use of novel second-line targeted therapies in non-small cell lung cancerErminia Massarelli, Roy S Herbst
Immunotherapy|February 11, 2016
Immune checkpoint therapy for non-small-cell lung cancer: an updateBing Xia, Roy S Herbst
Cancer Journal (Sudbury, Mass.)|August 8, 2014
B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future directionScott Gettinger, Roy S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Nivolumab and Pembrolizumab for Non-Small Cell Lung CancerDaniel Morgensztern, Roy S Herbst
Hematology/Oncology Clinics of North America|January 7, 2003
Angiogenesis as a target for cancer therapyKerim Kaban, Roy S Herbst
The Oncologist|November 11, 2008
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLCRoy S Herbst, Alan Sandler
The Journal of Clinical Investigation|June 5, 2008
To kill a tumor cell: the potential of proapoptotic receptor agonistsAvi Ashkenazi, Roy S Herbst
Pageof 40